Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant + Letrozole + Ribociclib in HR+/HER2- mBC
NCT05816655Phase 2Recruiting
- Sponsor
- Korea University Guro Hospital
- Start
- May 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in breast cancer, sponsored by Korea University Guro Hospital. Started May 2023; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05816655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816655.